According to the US Food and Drug Administration (FDA), Bristol Myers Squibb's heavyweight KRAS G12C inhibitor Krazati (adagrasib) has received accelerated approval again. It can be used in combination with cetuximab to treat locally advanced or metastatic colorectal cancer (CRC) in adult patients with KRAS G12C mutation confirmed by FDA-approved tests. These patients had previously received chemotherapy based on fluoropyrimidine, oxaliplatin, and irinotecan.
百时美施贵宝KRAS抑制剂再获FDA批准
Bristol-Myers Squibb's KRAS inhibitor receives FDA approval again.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.